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Letters to the Editor
ison performed for DBMI SDS was not signiﬁcant (p = 0.38)
(Fig. 1B). These results support the idea that it is the abdominal
fat (as expressed by W/Hr) more than the overall adiposity
(expressed by BMI), the external (not genetic) factor which mod-
ulates the effect of PNPLA3 148M allele on liver damage.
Exploring whether the PNPLA3 148M allele inﬂuences the abil-
ity of weight loss to decrease liver fat, Sevastianova et al. [6] inves-
tigated 18 subjects placed on a hypocaloric low-carbohydrate diet
for 6 days and demonstrated that weight loss is an effectiveway to
decrease liver fat, irrespective of the PNPLA3 genotype. Indeed,
short termweight loss decreases liver fat contentmore in homozy-
gous carriers of PNPLA3 148Mallele than in those carrying the 148I
allele. These results are in agreement with our data.
The mutant PNPLA3 148M allele is partially unable to hydro-
lyse intra-hepatocytic triglycerides [7,8], which increases the risk
of liver steatosis. Studies have also shown that there is about a
three-fold increase of PNPLA3 expression in obese human sub-
jects after the completion of a weight loss program [9]. It is pos-
sible, therefore, that the interaction between adiposity and
PNPLA3 may well be modulated by the effect of adipose tissue
changes on PNPLA3 expression.
An important clinical implication of the present study is that
obese children with fat liver carrying the PNPLA3 148M allele
are the patients who would most beneﬁt from weight loss.
Conﬂict of interest
The authors who have taken part in this study declared that they
do not have anything to disclose regarding funding or conﬂict of
interest with respect to this manuscript.
References
[1] Romeo S, Sentinelli F, Cambuli VM, Incani M, Congiu T, Matta V, et al. The
148M allele of the PNPLA3 gene is associated with indices of liver damage
early in life. J Hepatol 2010;53:335–338.1144 Journal of Hepatology 20
Open access under CC BY-NC-ND license.[2] Miraglia del Giudice E, Grandone A, Cirillo G, Santoro N, Amato A, Brienza C,
et al. The association of PNPLA3 variants with liver enzymes in childhood
obesity is driven by the interaction with abdominal fat. PLoS One
2011;6:e27933.
[3] Graff M, North KE, Franceschini N, Reiner AP, Feitosa M, Carr JJ, et al. PNPLA3
gene-by-visceral adipose tissue volume interaction and the pathogenesis of
fatty liver disease: the NHLBI family heart study. Int J Obes (Lond)
2013;37:432–438.
[4] Zampino R, Coppola N, Cirillo G, Boemio A, Pisaturo M, Marrone A, et al.
Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant
in the pathogenesis of liver steatosis in chronic hepatitis C. J Viral Hepat.
2013;20:517–523.
[5] Adams LA, White SW, Marsh JA, Lye SJ, Connor KL, Maganga R, et al.
Association between liver-speciﬁc gene polymorphisms and their expres-
sion levels with nonalcoholic fatty liver disease. Hepatology
2013;57:590–600.
[6] Sevastianova K, Kotronen A, Gastaldelli A, Perttilä J, Hakkarainen A, Lundbom
J, et al. Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to
weight loss-induced decrease in liver fat in humans. Am J Clin Nutr
2011;94:104–111.
[7] He S, McPhaul C, Li JZ, Garuti R, Kinch L, Grishin NV, et al. A sequence
variation (I148M) in PNPLA3 associated with nonalcholic fatty liver disease
disrupts triglyceride hydrolysis. J Biol Chem 2012;285:6706–6715.
[8] Huang Y, Cohen JC, Hobbs HH. Expression and characterization of a PNPLA3
protein isoform (I148M) associated with nonalcoholic fatty liver disease. J
Biol Chem 2011;286:37085–37093.
[9] Johansson LE, Danielsson AP, Parikh H, Klintenberg M, Norström F, Groop L,
et al. Differential gene expression in adipose tissue from obese human
subjects during weight loss and weight maintenance. Am J Clin Nutr
2012;96:196–207.Uncovering the molecular events associated with increased intestinal
permeability in liver cirrhosis: The pivotal role of enterocyte tight
junctions and future perspectivesTo the Editor:
We read with great interest the recently published research study
by Dr. Du Plessis and colleagues on the role of intestinal
macrophages in intestinal epithelial barrier dysfunction and
hyperpermeability in patients with cirrhosis [1]. The authors
demonstrated that decompensated liver cirrhosis was associated
with the presence of signiﬁcantly higher numbers of activated
intestinal macrophages (CD33+/CD14+/Trem-1+) expressing iNOS
and secretingNO and IL-6, in conjunctionwith increased duodenal
paracellular permeability and increased expression of the tight
junction (TJ) protein Claudin-2. They speculated that activation
of intestinalmacrophagesmight represent an importantmolecular
event implicated in the disruption of the intestinal epithelial
barrier in cirrhosis through secretion of TJ-regulating factors such
as NO and IL-6.
Despite the indisputable important pathophysiological role of
gut permeability alterations in the development of complications
of cirrhosis from diverse organs, little is known of its underlying
molecular and/or cellular mechanisms and relevant evidence
comes from extrapolation of data from animal studies. However,
animalmodels can never reproduce human diseases to the desired
level. Therefore, it is very positive that recent efforts focus on clin-
ical studies dealingwith this emerging concept; such studiesmight
endow us with a better understanding of the pathogenetic mecha-
nisms in humans. Our research group has recently shown, for the
ﬁrst time in humans, that altered expression of key structural13 vol. 59 j 1143–1149
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elements of enterocyte TJs might represent an important molecular
basis of increased intestinal paracellular permeability in cirrhosis
[2]. We have demonstrated in our study that the expression of the
TJ-related proteins occludin and claudin-1 was signiﬁcantly
decreased leading to increased gut permeability and endotoxemia.
Theﬁndings presented byDr. Du Plessis et al. provide additional evi-
dence on the importance of enterocyte TJs alterations as amolecular
mechanismunderlying the increase of intestinal permeability dem-
onstrating increased expression of Claudin-2. The difference in the
implicated TJ-relatedmolecules between the two studies is difﬁcult
to be fully explained presently. There is increasing awareness that
the building blocks of tight junctions, namely occludin and numer-
ous forms of claudins, serve tissue-speciﬁc and cell type-speciﬁc
needs, combining strict structural requirements and the need for
quick and versatile adaptive requirements [3]. Interactions between
enterocyte TJs macromolecules are certainly complex, depending,
apart from local cell-type speciﬁc factors, on concentration and
post-translational modiﬁcations [4]. Our knowledge on the role of
such factors is still rudimentary and, therefore, inmost cases it is dif-
ﬁcult to predict from mere expression levels the ﬁnal physiological
outcome. However, increased expression of claudin-2, as shown by
theauthors, aswell asdecreasedexpressionof claudin-1or occludin,
as shown in our study, all have been associated with a reduced
transepithelial resistance and increased paracellular permeability
in intestinal epithelial cells [5,6].
Of note, in the authors’ study, intestinal epithelial TJs altera-
tions were found only in patients with decompensated cirrhosis,
all of which had evidence of clinically signiﬁcant portal hyperten-
sion (ascites). Portal hypertension constitutes the pathophysiolog-
ical basis of most complications of cirrhosis and has been
previously shown to be strictly correlated with intestinal hyper-
permeability [7]. Therefore, a question raised is whether portal
hypertension is implicated as an early pathophysiological event
thatmight start the process of enterocyte TJs’ alterations in cirrho-
sis. As opposed to the authors’ study, we have previously shown
that altered expression of TJs proteins occurs not only in advanced
cirrhosis but in compensated cirrhosis aswell, where clinically sig-
niﬁcant portal hypertension (esophageal varices) was detected
only in half of the patients [2]. Despite the fact that we also dem-
onstrated an inverse correlation of esophageal varices grade (an
index of portal hypertension severity) with intestinal TJs expres-
sion in cirrhotic patients, our ﬁndings in early cirrhosis raise
doubts concerning the potential central role of portal hypertension
in intestinal TJs alterations. Clearly, future studies need to focus on
these questions, e.g., by investigating intestinal TJs in pre-hepatic
portal hypertensive animalmodels produced by partial portal vein
ligation.
Up to now, much attention has been paid to the role of luminal
factors (e.g., bacterial overgrowth) in enterocyte TJs regulation and
gut permeability alterations [8]. The role of themicrobiome should
be considered of major importance. In a recent review by Wells
et al. [9], the epithelial crosstalkwith the ‘‘inner’’ and ‘‘outer’’ envi-
ronment has been discussed and in this context the role of Toll-like
receptors (TLR) has been emphasized. Further support for this
notionhas beenprovidedby in vivo studies showing that TLR-2 sig-
naling in mucosal monocytes and TLR-4 in enterocytes are impli-
cated in intestinal epithelial barrier dysfunction [10,11]. The
recently published study by Du Plessis and colleagues, investigat-
ing further themolecular events implicated in intestinal hyperper-
meability in patients with liver cirrhosis, adds the underlying
lamina propria as an important compartment, pointing to macro-
phages as critical players in the process. We can anticipate that
in the future another compartment may be added: that of epithe-
lial cells in the vicinity, which by laterally releasing critical medi-
ators in an autocrine fashion (either directly or via exosomes)
may play a role in spreading alterations in intestinal permeability.
Regarding the potential mechanism(s) of regulation of entero-
cyte TJs formation and function, the authors propose that IL-6
and NO released by activated intestinal macrophages might exert
an important role. It has been shown by the important study of
Hartmann and colleagues that inﬂammatory mediators released
locally from intestinal monocytes might disrupt enterocyte TJs
through activation of the Rho GTPase pathway which leads to
myosin light chain phosphorylation [10]. This pathway has been
implicated in displacement and reorganization of TJ macromole-
cules [12]. However, beyond the implication of altered signaling,
the regulation of expression of enterocyte TJ components and the
resulting formation and functionality of the TJ can be anticipated
to happen at several levels. First at the transcriptional level,
where a combination of transcription factors and regulatory ele-
ments (close or at a distance from the promoter) can inﬂuence
the initiation and efﬁciency of the transcriptional machinery. Sec-
ond, following transcription, at the stability of the generated
message, where a constellation of RNA molecules (mainly
microRNAs) can inﬂuence the produced protein. Finally, at the
level of post-translational modiﬁcations, where several additions
(especially of phosphate groups but not restricted to them) can
affect protein trafﬁcking and TJ formation and degradation. We
propose that in future studies special emphasis should be put
on the role of microRNAs, as initial studies indicate an important
role [13]. Although this ﬁeld is at a very early stage, the promise
for speciﬁc pharmaceutical interventions for enterocyte TJs
should be underlined.
In conclusion, we think that the alterations of enterocytes’ TJs
is the critical anatomical change which, by a combination of
molecular mechanisms that we just start to uncover, is leading
to intestinal hyperpermeability in patients with cirrhosis. In our
view, we have reached a point where there is an emerging need
to generate more data on human material by adopting two meth-
odological approaches: ﬁrst, larger numbers of human samples
should be used, taken from certiﬁed biobanks with detailed case
history; second, this precious material should be subjected to
study with Systems Biology approaches, namely using genomics,
transcriptomics and, more importantly, proteomics for the analy-
sis of samples. Such global biology approaches will certainly
allow us to discover novel macromolecules and regulatory path-
ways for enterocyte TJ formation, function and turnover. The fact
that these methodologies can be applied to formalin ﬁxed paraf-
ﬁn embedded material existing in Pathology Departments should
generate more incentive to pathologists to contribute to this ﬁeld
in the near future [14,15]. However, the –omics approaches can
give us a wealth of information regarding macromolecules and
their involvement in discrete pathways but will not allow us to
reach an in depth understanding without the performance of par-
allel physiological studies assessing intestinal permeability and
barrier function. Intestinal permeability assessment in humans
could be performed with the use of differentially sized orally
administered non-metabolizable probes and measuring their uri-
nary excretion or by ex vivo set ups like Ussing chambers, whilst
gut barrier integrity could be assessed using markers of patholog-
ical bacterial translocation e.g., serum levels of endotoxin, anti-
endotoxin antibodies, lipopolysaccharide binding protein orJournal of Hepatology 2013 vol. 59 j 1143–1149 1145
detection of bacterial DNA by polymerase chain reaction tech-
nique in blood. In addition, more sophisticated techniques using
ﬂuorescent markers to monitor trans-epithelial permeability and
providing us with real-time information with in vivo imaging
could be developed. The combination of the approaches
suggested above will lead to a more global understanding of
the pathophysiology of enterocyte TJs in human liver cirrhosis
and to the discovery of more speciﬁc targets (disrupting a
signaling pathway, interfering with a regulatory RNA or protein
molecule, others) and will likely lead to more effective and
potentially individualized pharmacological control of intestinal
hyperpermeability, thus preventing the endotoxin-associated
systemic complications and improving clinical outcome..
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Reply to: ‘‘Uncovering the molecular events associated with increased
intestinal permeability in liver cirrhosis: The pivotal role
of enterocyte tight junctions and future perspectives’’
To the Editor:
We thank Assimakopoulos and colleagues for their interest in our
recent article [1]. As suggested, important efforts are being made
to understand why the intestinal barrier fails in cirrhosis and the
mechanism by which viable bacteria translocate from the gastro-
intestinal tract.
In our study, we assessed the following:
Firstly, we studied the morphology and function of the intesti-
nal barrier in decompensated and compensated ASH/NASH cir-
rhotic patients. We could show that the morphology of the
intestinal barrier was intact at the ultrastructural level, suggesting
that permeabilitywas functionally altered andnot just secondarily
increased due towidened intracellular junctions induced by portal
hypertension [2,3]. At a functional level, we could indeed conﬁrm
that transepithelial resistance was decreased and permeability
increased inpatientswithdecompensated cirrhosis.We fully agree
with the comments by Assimakopoulos et al. that emphasize the
important role of TJ proteins in intestinal barrier function in cirrho-
sis as demonstrated in their recent study [4]. The difference in the
implicated TJ proteins between our study [1] and that of Assimak-
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